Noema Pharma raised $147 Million in a Series B financing round led by EQT Life Sciences to support its Phase 2 trials for CNS disorders.

Dec 11, 2024•about 1 year ago

Amount Raised

$147 Million

Round Type

series b

BaselTherapeuticsBiotechnologyHealth Care

Investors

Upmc EnterprisesInvusPolaris PartnersGilde HealthcareSofinnova PartnersJeito CapitalForbionEqt Life Sciences

Description

Noema Pharma successfully closed a Series B extension financing round with an investment from EQT Life Sciences, bringing the total capital raised to approximately $147 million. This financing will support Noema Pharma’s four active Phase 2 trials, with key data readouts anticipated in 2025.

Company Information

Company

Noema Pharma

Location

Basel, Basel-Stadt, Switzerland

About

Noema Pharma is a clinical-stage biotech company advancing a portfolio of transformative, first-in-disease therapeutics targeting neuroscience-based conditions with high unmet need. Noema has four programs currently in active Phase 2 clinical trials evaluating seizures in Tuberous Sclerosis Complex, pain in Trigeminal Neuralgia, Tourette syndrome and vasomotor symptoms plus CNS-mediated symptoms of menopause with readouts expected in 2025. Noema was founded by leading venture capital firm Sofinnova Partners and is supported by current investors including EQT Life Sciences, Forbion, Gilde Healthcare, Invus, Jeito Capital, Polaris Partners and UPMC Enterprises.

Related People

4 contacts

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends